Brief: Pharnext H1 net loss widens to 8.0 mln euros
Oct 27 (Reuters) - Pharnext SAS PHARN.PA :
* Reports H1 operating loss of 5.7 million euros ($6.2
million) versus loss of 4.0 million euros a year ago
* H1 net loss is 8.0 million euros versus loss of 5.2
million euros a year ago
* Cash position at end June 2016 is 5.0 million euros versus
2.3 million euros a year ago
* Phase 2A results of PXT864 in alzheimer treatment will be
presented in Dec. 2016
Source text for Eikon: ID:nBw8Cx3ffa
Further company coverage: PHARN.PA
($1 = 0.9167 euros)
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development